2024-516025-30-00RecruitingPhase 2
[18F]Tetrafluoroborate PET/CT for the Detection of Differentiated Thyroid Cancer: A Phase II Imaging Study
Source: EU CTIS (euclinicaltrials.eu) · Last updated 2 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
a) To determine the optimal time point acquisition of [18F]TFB PET/CT, b) to determine the value of [18F]TFB PET/CT for detection of (pre-operative) metastatic lymph node(s) in patients with differentiated thyroid cancer and c) to determine the value of [18F]TFB PET/CT for the estimation of radioiodine therapy response in patients with persistent and recurrent differentiated thyroid cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 3 Dec 2024
- Start date
- 1 Sept 2025
- Lead sponsor
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Diseases
- Thyroid cancer
- EU CT number
- 2024-516025-30-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 40
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with differentiated thyroid cancer. Some have newly found cancer in lymph nodes and are referred for surgery. Others are referred for 131I therapy.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Group 1: newly diagnosed differentiated thyroid cancer with lymph node metastases proven by pathology, referred for surgery. Group 2: differentiated thyroid cancer referred for 131I therapy.
- Earlier treatment
- Cannot have had iodine (for example iodinated contrast agent) or perchlorate within the past 2 months.
Main reasons for not taking part
- Mentally or legally incapacitated
- Pregnant or breastfeeding
- Iodine or perchlorate exposure within the past 2 months
- Takes lithium
- Takes amiodarone
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Lab values
- Patient is mentally or legally incapacitated - Patient is pregnant or lactating - Patient has been subjected to an excess of substrates of the sodium iodine symporter such as iodine (e.g. in the form of iodinated contrast agent) or perchlorate within the past 2 months. - Patient takes lithium - Patient takes amiodarone
Who the study is looking for
- Group 1: patients with newly diagnosed differentiated thyroid cancer and pathologically proven lymph node metastases thyroid cancer referred for surgical resection - Group 2: patients with differentiated thyroid cancer referred for 131I therapy - The patient has provided written informed consent authorization before participating in the study - The patient is ≥ 18 years old - The patient has an ECOG status grade 0-2
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Rotterdam | Netherlands | Recruiting |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.